Clinical Trials Browser

Phase 2/3 × INDUSTRY × brigimadlin × Clear all

NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2/3 Completed

400 enrolled 15 charts

Liposarcoma